Figure 3
Trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells (PBMCs) cultured with IL-21. PBMCs derived from patients (oesophageal squamous cell carcinoma (ESCC)) and healthy donors (healthy) were cultured with IL-21 at the indicated doses (1, 5, and 10 μg ml−1) for 24 h. Thereafter, cultured PBMCs were subjected to Trastuzumab-mediated ADCC against high HER2-expressing TE4 and low HER2-expressing KYSE50 at the indicated effector : target ratios (10 : 1, 20 : 1, and 40 : 1). (A) Representative data showed that Trastuzumab-mediated ADCC was enhanced by the addition of IL-21. (B) Summarised data from patients (ESCC, n=8) and healthy donors (healthy, n=6) showed that IL-21 significantly enhanced Trastuzumab-mediated ADCC in a dose-dependent manner. **P<0.01. *P<0.05. The expression of HER2 on target tumour cells was shown as mean fluorescence intensity (MFI) analysed by flow cytometry.
